KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Change in Cash (2016 - 2026)

Bio-Rad Laboratories has reported Change in Cash over the past 18 years, most recently at -$23.2 million for Q1 2026.

  • Quarterly Change in Cash fell 169.67% to -$23.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$14.1 million through Mar 2026, down 115.79% year-over-year, with the annual reading at $42.4 million for FY2025, 50.35% down from the prior year.
  • Change in Cash was -$23.2 million for Q1 2026 at Bio-Rad Laboratories, down from $134.0 million in the prior quarter.
  • Over five years, Change in Cash peaked at $331.5 million in Q1 2022 and troughed at -$205.7 million in Q2 2022.
  • The 5-year median for Change in Cash is $4.5 million (2024), against an average of $2.2 million.
  • Year-over-year, Change in Cash surged 3030.82% in 2022 and then plummeted 480.08% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$83.7 million in 2022, then soared by 35.65% to -$53.9 million in 2023, then surged by 244.05% to $77.6 million in 2024, then soared by 72.68% to $134.0 million in 2025, then plummeted by 117.31% to -$23.2 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Change in Cash are -$23.2 million (Q1 2026), $134.0 million (Q4 2025), and $26.5 million (Q3 2025).